The predictive value of C-reactive protein in end-stage renal disease: Is it clinically significant?

Blood Purification

Volumn 24, Issue 4, 2006, Pages 335-341

  Van Der Sande, Frank M ^a   Kooman, Jeroen P ^a   Leunissen, Karel M L ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C reactive protein; End stage renal disease; Predictive value, C reactive protein

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6;

ANALYTICAL PARAMETERS; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BIODIVERSITY; BONE METABOLISM; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; KIDNEY FAILURE; LIFESTYLE; MINERAL METABOLISM; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS; STROKE; VASCULAR DISEASE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL DIALYSIS;

EID: 33747084051     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092279     Document Type: Review

References (47)

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
2. Keys A: Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, Harvard University Press, 1980.
3. Hackam DG, Anand SS: Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932-940.
4. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 1998;32(suppl 3):S112-S119.
5. Collins AJ, Shuling L, Ma JZ, Herzog C: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001;38(suppl 1): S26-S29.
6. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
7. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-466.
8. Libby P, Ridker PM: Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148-1150.
9. Tracy RP: Inflammation in cardiovascular disease: cart, horse, or both. Circulation 1998;97:2000-2002.
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
11. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141.
12. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486-1491.
13. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrel K, Tracy RP, Rubin SM, Harris TB, Pahor M: Inflammatory markers and cardiovascular disease: the Health, Aging and Body Composition (Health ABC) Study. Am J Cardiol 2003;92:522-528.
14. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-1688.
15. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004;19:1154-1160.
16. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimburger O, Holmes C, Schalling M, Nordfors L: Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-2392.
17. Tripepo G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16(suppl 1):S83-S88.
18. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919
19. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.
20. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
21. Pasceri V, Chang JS, Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
22. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, MIckle DA: C-reactive protein activates the NFκB signalling pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003;126:1886-1891.
23. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko PE, Li RK, Mickle DA, Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-1790.
24. Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PW, Li RK, Mickle DA, Verma S: C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004;109:833-836.
25. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-1392.
26. Stenvinkel P, Lindholm B: C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005;23:72-78.
27. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
28. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
29. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-512.
30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
31. Ford ES, Giles WH, Mokdad AH, Myers GL: Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004;50:574-581.
32. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
33. Smith SC Jr, Anderson JL, Cannon RO 3rd, Fadl YY, Koenig W, Libby P, Lipshultz SE, Mensah GA, Ridker PM, Rosenson R; CDC; AHA: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation 2004;110:e550-e553.
34. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005;67:1216-1233.
35. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997;29:658-668.
36. van Tellingen A, Grooteman MP, Schoorl M, Bartels PC, Schoorl M, van der Ploeg T, ter Wee PM, Nube MJ: Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002;62:632-638.
37. Beerenhout CH, Kooman JP, van der Sande FM, Hackeng C, Leunissen KM: C-reactive protein levels in dialysis patients are highly variable and strongly related to co-morbidity. Nephrol Dial Transplant 2003;18:221.
38. Nakamura A, Suzuki T, Kohsaka T: Renal tubular function modulates urinary levels of interleukin-6. Nephron 1995;70:416-420.
39. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-1218.
40. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844.
41. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
42. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
43. März W, Winkler K, Nauck M, Böhm BO, Winkelmann BR: Effects of statins on C-reactive protein and interleukin-6: the Ludwigshafen Risk and Cardiovascular Health study. Am J Cardiol 2003;92:305-308.
44. Bhatt DL, Topol EJ: Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-140.
45. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T: Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17:1513-1517.
46. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002;39:1213-1217.
47. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.